Rxight® Advances President’s Precision Medicine Initiative

WASHINGTON, May 16, 2016  — In an effort to expand upon President Obama’s Precision Medicine Initiative and explore innovative ways to individualize patient care, representatives from MD Labs met with Senior Leadership at the White House Office of Science and Technology Policy (OSTP).

 

During their visit, the team discussed how Rxight®, the most comprehensive pharmacogenetic program available, helps people receive the right medication and dosing, and avoid medications that could cause unintended side effects and complications. Rxight® uses state-of-the-art pharmacogenetic testing technology that focuses on the patient’s DNA, rather than relying on a process of trial and error to predict medication response President Obama alluded to this technology on January 30, 2015, in his remarks on Precision Medicine when he said, “What if figuring out the right dose of medicine was as simple as taking our temperature? And that’s the promise of precision medicine—delivering the right treatments, at the right time, every time to the right person.”

 

“We’re proud to support this promising initiative that will help change how medicine is practiced today and in the future,” said Denis Grizelj, Co-Founder/CEO of MD Labs, creators of the Rxight® program. “We want to help healthcare providers maximize their clinical care, and through Rxight they can be further assured that the medications they prescribe are tailored for their patients and can reduce the risk of side effects.”

 

The Rxight® pharmacogenetic program is truly unique because it covers over 210 prescription and over-the-counter (OTC) medications, and includes a Personalized Medication Review® with a Rxight® Certified Pharmacist. Through a simple cheek swab, the test can identify key genetic markers that highlight how a patient’s body metabolizes and processes different medications. People who choose to get the test receive a lifetime of benefits as medication needs are expected to change as one ages.  “With Rxight, we can identify how genetic variation can lead to unintended medication consequences that may contribute to patients not taking their medication as prescribed and also help reduce long-term health care costs of medications not suited for that individual.” said Dr. Amina Abubakar, a Rxight® Certified Pharmacist running her own pharmacy in Charlotte, North Carolina.

About Rxight®

Developed by MD Labs, a leading high-complexity CLIA certified laboratory specializing in clinical lab testing, Rxight® is the most comprehensive pharmacogenetic program for prescription and OTC medication users. Founded in 2011, MD Labs serves healthcare providers across the United States. Employing state-of-the-art technology and testing for a wide array of analytes, our team of PhDs and clinical technologists are able to keep ahead of the needs of the medical community. Constantly adding services based on client requests and pharmacotherapeutic trends, allows us to provide quick, accurate and cost-effective testing while enhancing patients’ medication therapies, prescription adherence and overall patient care.

 

About President Obama’s Precision Medicine Initiative

In the 2015 State of the Union address, the president announced the launch of the Precision Medicine Initiative—a bold new research effort to revolutionize how we improve health and treat disease. Until now, most medical treatments have been designed for the “average patient.” As a result of this “one-size-fits-all” approach, treatments can be very successful for some patients but not for others. Precision Medicine, on the other hand, is an innovative approach that takes into account individual differences in people’s genes, environments and lifestyles. It gives medical professionals the resources they need to target the specific treatments of the illnesses we encounter, further develops our scientific and medical research, and keeps our families healthier. For more information on the Precision Medicine Initiative, visit whitehouse.gov/precision-medicine.